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Background: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO,
ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous
(SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of
ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females)
and 8 sheep (Ovis aries, four males and four females) 12–16 months old and weighing 20–32 kg, were used. The study
was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16
goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats)
animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the
sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received
ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the
jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and
its metabolites were analysed by high performance liquid chromatography.
Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller
and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of
5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC
administration at increased doses (10 and 15 mg/kg) in goats.
Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration
and thus to achieve greater efficacy against the target parasites.
Keywords: Benzimidazoles, Albendazole, Albendazole Sulfoxide, Pharmacokinetics, Enantiomers, Sheep, GoatBackground
Benzimidazole (BZD) and pro-BZD drugs are used widely
to treat gastrointestinal helminthiasis including migrating
larvae, liver flukes and lungworm infections in animals with
a broad spectrum of activity and low mammalian toxicity
[1]. The parent molecules of BZD anthelmintics are ex-
tensively metabolised in all animal species and the parent
drug is short-lived and metabolic products predominate
in systemic circulation. The primary metabolites, usually* Correspondence: cengizgokbulut@yahoo.com
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and water soluble than the parent drug. The poor water
solubility reduces flexibility for drug formulation of the
most potent BZD methylcarbamate anthelmintics such as
albendazole (ABZ) and fenbendazole (FBZ), allowing their
formulation only as tablets, boluses or suspensions for per
os/intraruminal administration in ruminants [1]. After ab-
sorption from the intestine in ruminants, ABZ is rapidly
metabolized into its anthelmintically active albendazole
sulfoxide (ABZ-SO) and inactive albendazole sulfone (ABZ-
SO2) metabolites by liver enzymes [2].
ABZ-SO, known as ricobendazole, is chemically the
sulfoxide derivative of ABZ being the most importanthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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atically after ABZ treatment in sheep [3–6] and cattle
[7, 8]. ABZ-SO is much more water soluble compared
with ABZ. An injectable formulation of ABZ-SO has
been developed for subcutaneous (SC) administration
in cattle and sheep. This formulation has some advan-
tages compared with the other formulations for per os
or intraruminal administration, as drug molecules are
potentially freely available for absorption from the
injection site, avoiding the first-pass effect and actions
of the oesophageal groove [8]. The gastrointestinal and
the first-pass metabolism are common metabolic path-
ways for sulfoxide BZDs and they are metabolised into
their sulfoxides, which in turn are oxidized into the
more polar and less anthelmintically active sulfone
metabolites following per os administration in different
animal species.
Sulfoxide BZDs [ABZ-SO and oxfendazole (OFZ)] which
have a chiral centre about the sulfur atom are formed as
metabolites of sulfides and are metabolised into sulfones.
Pharmacodynamic and pharmacokinetic properties of
enantiospecific pairs are commonly different and are of
major importance for their effective and safe thera-
peutic use. The sulfones are anthelmintically inactive,
whereas sulfides and sulfoxides are both active [9]. Al-
though the plasma dispositions of two enantiomers of
ABZ-SO and OFZ have been investigated in many spe-
cies after per os administration of the pro-chiral ABZ,
FBZ and racemic ABZ-SO and OFZ [10–19], there is a
paucity of data available in the literature on the stereo-
specific plasma behaviour of the enantiomers of ABZ-
SO following intravenous (IV) and SC administration
of rac-ABZ-SO in goats.
Due to a shortage of registered drugs available for
goats in most countries, different classes of drugs, in-
cluding anthelmintics licensed for sheep are extensively
used in goats without optimization of dosing regimens
and determination of pharmacokinetic and pharmacody-
namic properties [20]. It is generally acknowledged that
the plasma disposition and metabolism of anthelmintic
drugs are different between sheep and goats [21–25].
Goats metabolise and eliminate anthelmintic compounds
more rapidly from blood compared with sheep. The
presence of the metabolic differences between two spe-
cies has been not considered for many years. The high
prevalence of anthelmintic-resistant nematodes in goats
are probably due to the extensive extra-label use of these
compounds at a standard ovine dosage, corresponding
to a drug under-dosing and leading to reduced efficacy
of the drug [26, 20]. Therefore, the present study was
designed to compare the pharmacokinetic and bioavail-
ability of ABZ-SO in goats and sheep following IV and
SC administrations at a dose rate of 5 mg/kg bodyweight
(BW) and to investigate the effects of increased doses(10 and 15 mg/kg) on the plasma disposition of ABZ-SO
in goats following SC administration. In addition, the
stereospecific disposition of enantiomers [(+) ABZ-SO
and (−) ABZ-SO)] was also determined and compared in
both species after IV and SC administrations of racemic
(rac)-ABZ-SO.
Results
The analytical procedures for the determination of plasma
concentrations of ABZ, albendazole-2-aminosulfone
(ABZ-NH3), ABZ-SO and ABZ-SO2 were validated be-
fore analysing of the experimental samples and the val-
idation parameters for all molecules are summarised in
Table 1. ABZ and ABZ-NH3 were not detected in any
plasma samples of sheep and goats following either
IV or SC administrations. The plasma concentration vs.
time curves of ABZ-SO and ABZ-SO2 are shown in
Fig. 1 and the pharmacokinetic data are summarized in
Table 2 following IV administration in goats and sheep.
Although the absorption phase and peak plasma concentra-
tions (Cmax) of ABZ-SO were similar in both species, the
area under the curve (AUC), terminal half-life (T1/2) and
plasma persistence (MRT) values were smaller and shorter,
respectively, in goats compared with those observed in
sheep after SC administration at a dose of 5 mg/kg BW.
The plasma concentrations of (+) ABZ-SO and (−) ABZ-
SO) vs. time curves of ABZ-SO in goats and sheep follow-
ing IV administrations at a dose rate of 5 mg/kg BW are
shown in Fig. 2 and 3, respectively. In addition, the com-
parative ratio of the percentage of enantiomers in goats and
sheep following IV administrations is shown in Fig. 4 and
kinetic parameters of each enantiomer are summarised in
Table 3. Stereospecific disposition of enantiomers displayed
similar disposition in sheep and goats. (+) ABZ-SO were
predominant and displayed significantly higher plasma con-
centrations compared with (−) enantiomer. The AUC of (+)
enantiomer was almost two times larger than that of (−) en-
antiomer in both species after IV administration of rac-
ABZ-SO.
The plasma concentration vs. time curves of ABZ-SO
and ABZ-SO2 are shown in Fig. 5 and 6, respectively. Mean
(±SD) pharmacokinetic parameters of ABZ-SO and its me-
tabolite ABZ-SO2 in goats and sheep at a dose rate of
5 mg/kg and at increased doses (10 and 15 mg/kg BW) in
goats following SC administrations are summarized in
Table 4 and 5, respectively. Dose-dependent plasma dispo-
sitions of ABZ-SO were observed following SC administra-
tion at increased doses (10 and 15 mg/kg BW) in goats. In
addition, the mean plasma concentrations of enantiomers
vs. time curves of ABZ-SO are shown in Fig. 7. The mean
kinetic parameters of both enantiomers in goats and sheep
at a dose of 5 mg/kg BW and at increased dose rates
(10 and 15 mg/kg BW) in goats following SC adminis-
trations are given in Table 6.
Table 1 Validation of analytical method used for determination
of ABZ, ABZ-NH3, ABZ-SO and ABZ-SO2 concentrations in
plasma
ABZ-NH3 ABZ-SO ABZ-SO2 ABZ
LOD (μg/ml) 0.015 0.016 0.016 0.017
LOQ (μg/ml) 0.042 0.045 0.045 0.050
Range of linearity
(μg/ml)
0.05-20 0.05-20 0.05-20 0.05-20
Linearity (r2) 0.997 0.999 0.998 0.996
Recovery (%) 63.69 (5.42) 94.10 (6.39) 91.90 (4.88) 69.29 (6.21)
Coefficient of
variation (%)
6.89 5.35 6.33 7.75
Retention times
(min)
5.37 5.77 6.81 9.95
LOD limit of detection, LOQ limit of quantification. Values in the brackets represent
the coefficient of variations for the recovery assays, r: correlation coefficient
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The present study showed that the AUC and MRT values
of ABZ-SO in goats were significantly smaller and shorter
compared with those observed in sheep. Moreover, T1/2 of
ABZ-SO was significantly shorter in goats compared with
that observed in sheep following IV and SC administra-
tions at a dose of 5 mg/kg BW. The origin of the lower
plasma concentration in goats is unclear. The most likely
explanation for the origin of these kinetic differences is
that goats have a greater metabolic capacity and elimin-
ation capability of ABZ-SO in comparison with sheep.
Previous studies indicated that the plasma disposition and
metabolism of anthelmintic drugs are different between
sheep and goats [21–25]. It has been commonly acknowl-




















Fig. 1 Comparative mean (±SD) plasma concentration vs. time curves of ABZ-S
at a dose of 5 mg/kg (n = 8)metabolised and eliminated from blood in goats compared
with sheep. This difference has been shown for different
anthelmintic compounds, including BZDs [19, 21, 27–29]
endectocides [24, 30, 31], levamisole, [25, 32] and oxyclo-
zanide [25]. The greater ability to detoxify exogenous
compounds, including anthelmintics, has been attributed
to the specific feeding behaviour of goats [33], since the
feeding behaviour of goats is quite different compared
with that of sheep. Sheep are known as grazers, preferring
to feed on grass and forbs, whereas goats are described as
ingesting substantial amounts of browse (woody plants,
vines and brush). Thus, goats are better adapted to toler-
ate and detoxify plant toxins and exogenous compounds
compared with sheep [34, 35].
The plasma disposition of ABZ-SO has been previously
reported in sheep after IV and SC administration at a dose
of 5 mg/kg BW [8]. Some findings in the present study
(T1/2: 5.57 h, AUC: 39.15 μg.h/mL, MRT: 7.44 h, Cl: 0.13
L/h/kg and Vdss: 1.04 L/kg) are similar to those obtained by
Formentini et al. [8] (T1/2: 5.19 h, AUC: 29.6 μg.h/mL,
MRT: 6.4 h, Cl: 0.17 L/h/kg and Vdss: 1.3 L/kg) in sheep fol-
lowing IV administration at a same dose rate (5 mg/kg
BW). On the other hand, although Cmax (2.05 μg/mL vs.
2.09 μg/mL), T1/2 (MRT (13.00 h vs. 10.4 h) and F (97.9 %
vs. 96.0 %) values of ABZ-SO are similar, the AUC
(38.35 μg.h/mL vs. 28.4 μg.h/mL) Tmax (8.5 h vs. 3.81 h),
and MAT (5.56 h vs. 3.14 h) values are larger and longer
than those reported by Formentini et al. [8] in sheep, re-
spectively. The origin of the differences between the studies
is unclear. These differences between the studies may be at-
tributable to differences in methodology or experimental






O and ABZ-SO2 in goats and sheep following intravenous administrations
Table 2 Comparative mean (±SD) kinetic parameters of ABZ–SO and ABZ–SO2 in goats and sheep following intravenous
administrations at a dose of 5 mg/kg (n = 8)
Parameters Goat Sheep
ABZ-SO ABZ-SO2 ABZ-SO ABZ-SO2
T1/2λz (h) 5.43 ± 0.89* 3.53 ± 0.81* 6.57 ± 0.73 11.43 ± 9.41
Cmax (μg/mL) - 0.62 ± 0.21 - 0.46 ± 0.05
C0 (μg/mL) 10.84 ± 1.81 - 10.86 ± 1.82 -
Tmax (h) - 15.00 ± 6.48* - 8.50 ± 3.34
Tlast (h) 21.00 ± 4.14* 25.00 ± 10.56 30.00 ± 3.70 31.00 ± 2.83
AUClast (μg.h/mL) 34.10 ± 5.31* 10.49 ± 4.26 39.15 ± 5.59 11.00 ± 0.78
AUCMlast (μg.h2/mL) 201.91 ± 58.84* 133.34 ± 65.25 293.46 ± 64.66 155.96 ± 17.30
Cl (L/h/kg) 0.14 ± 0.03 - 0.13 ± 0.02 -
MRTlast (h) 5.81 ± 0.86* 12.31 ± 4.95 7.44 ± 1.03 14.18 ± 1.28
Vdss (L/kg) 0.94 ± 0.09 - 1.04 ± 0.14 -
T1/2λz terminal half-life; Cmax peak plasma concentration; C0 plasma concentration at time 0; Tmax time to reach peak plasma concentration; Tlast time to last detectable plasma
concentration; AUClast area under the (zero moment) curve from time 0 to the last detectable concentration; AUCM area under the moment curve from time 0
to t last detectable concentration; Cl clearance of drug; MRTlast mean residence time; Vdss volume of distribution at steady-state
*The parameters in goats are significantly different from those in sheep (*P < 0.05)
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ferences in absorption, disposition and persistence of an-
thelmintic drugs in the animals.
The results obtained in the present study indicate that
an increase in ABZ-SO dosage in goats is associated with
elevation in the plasma level of ABZ-SO. Significantly
higher AUC and Cmax values for ABZ-SO were observed
after SC administration at both dose rates of 10 and
15 mg⁄ kg compared to the treatment at 5 mg⁄ kg
(Table 2). The AUC of ABZ-SO increased from 29.76
(5 mg/kg) to 62.19 (10 mg/kg) and to 112.66 μg.h/mL





















Fig. 2 Mean (±SD) plasma concentrations of enantiomers [(+)ABZ-SO and
administrations at a dose of 5 mg/kg (n = 8)previous study performed by Alvarez et al. [36] who in-
dicated that increasing the dose of ABZ (5, 15, 45 mg/kg
BW) is associated with enhanced plasma level and ex-
posure of ABZ metabolites in sheep after intraruminal
administration.
The plasma dispositions of the two enantiomers of
ABZ-SO have been investigated in many species after
oral administration of the pro-chiral ABZ [10–12, 15–18,
29], and after IV and per os administration of ABZ-SO in
sheep [5, 17] which is discussed by Capece et al. [37]. In
addition, it has been shown that (+) ABZ-SO was anthel-




(−)ABZ-SO)] vs. time curves of ABZ-SO in goats following intravenous























Fig. 3 Mean (±SD) plasma concentrations of enantiomers [(+)ABZ-SO and (−)ABZ-SO)] vs. time curves of ABZ-SO in sheep following intravenous
administrations at a dose of 5 mg/kg (n = 8)
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spiralis infection [38].
The current study also showed that the enantiomers of
ABZ-SO were never in racemic proportions and the enan-
tiospecific ratio (+/−) of plasma concentration of ABZ-SO
changed over time in favour of the (+) enantiomer in sheep
and goats after both IV and SC administration of rac-ABZ-
SO. The AUC of the (+) enantiomer was almost 2 times lar-
ger than that of (−) enantiomer of ABZ-SO, in agreement


























 (+) ABZ-SO (Sheep)
 (-) ABZ-SO (Sheep)
 (+) ABZ-SO (Goats)
 (-) ABZ-SO (Goats)
Fig. 4 Comparative ratio of the percentage of enantiomers (ABZ-SO and (−
intravenous administrations at a dose of 5 mg/kg (n = 8)who indicated that (+) enantiomer represented 85 and 80 %
of the total plasma AUC of ABZ-SO in male and female
sheep, respectively. This may contribute to the anthelmintic
effect of the (+) ABZ-SO enantiomer since it has been
shown that (−) ABZ-SO is quickly metabolised into the in-
active sulfone [17]. It has been demonstrated that the flavin
monooxygenase (FMO) system is enantioselective in favour
of the (+) sulfoxide of ABZ, whereas only cytochrome P450
systems specifically produce (−) ABZ-SO which was shown
to be the main substrate for the formation of the inactive10 12 14 16 18
e (h)
) ABZ-SO) vs. time curves of ABZ-SO in goats and sheep following
Table 3 Comparative mean (±SD) kinetic parameters of (−)
ABZ-SO and (+) ABZ-SO in goats and sheep following
intravenous administrations at a dose of 5 mg/kg (n = 8)
Parameters Goat Sheep
(−) ABZ-SO (+) ABZ-SO (−) ABZ-SO (+) ABZ-SO
T1/2λz (h) 3.66 ± 0.66* 8.03 ± 1.67 3.98 ± 0.64* 9.36 ± 2.23
Cmax
(μg/mL)
2.32 ± 0.40 2.11 ± 0.33 2.33 ± 0.27 1.95 ± 0.29
Tlast (h) 15.43 ± 1.51* 20.57 ± 4.28 17.00 ± 2.83* 30.00 ± 3.70
AUClast
(μg.h/mL)
11.73 ± 2.43* 18.45 ± 5.62 11.96 ± 1.50* 20.53 ± 3.90
AUCMlast
(μg.s2/mL)
51.33 ± 16.00 135.35 ± 62.98 55.53 ± 9.48* 186.82 ± 49.46
Cl (L/h/kg) 0.42 ± 0.10* 0.24 ± 0.06 0.40 ± 0.06 0.24 ± 0.06
MRTlast (h) 4.29 ± 0.57* 7.07 ± 1.20 4.63 ± 0.38* 8.98 ± 1.44
Vdss (L/kg) 2.05 ± 0.24 2.53 ± 0.41 2.23 ± 0.27 2.47 ± 0.30
T1/2λz terminal half-life; Cmax peak plasma concentration; Tlast time to last
detectable plasma concentration; AUClast area under the (zero moment)
curve from time 0 to the last detectable concentration; AUCM area under the
moment curve from time 0 to t last detectable concentration; Cl clearance of drug;
MRTlast mean residence time; Vdss: volume of distribution at steady-state
*Differences between the enantiomers in the same animal species (P < 0.05)
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enantioselectivity could be explained by different metabolic
enzyme contributions.
Conclusion
Although the absorption phase and the peak plasma
concentration of ABZ-SO were similar in both species,
the plasma availability, elimination and persistence of






















Fig. 5 Comparative mean (±SD) plasma concentration vs. time curves of A
dose rate of 5 mg/kg and at increased dose rates (10 and 15 mg/kg) in gocompared with those observed in sheep, respectively, fol-
lowing SC administrations at a dose of 5 mg/kg BW. As
a consequence, treatment of goats with ABZ-SO at the
recommended sheep dose may result in reduced anthel-
mintic efficacy, which may increase the risk of drug re-
sistance in internal parasites. Moreover, it was also
shown that increasing the dose of ABZ-SO in goats was
associated with enhanced plasma exposures after SC ad-
ministration. Therefore, increased doses could be a strat-
egy to provide higher and more persistent plasma
concentration and thus to improve the efficacy against
the target parasites and to delay the development of an-
thelmintic resistance in goat parasites.
Methods
Experimental animals
A total of 16 goats (Capra aegagrus hircus, eight male
and eight female) and 8 sheep (Ovis aries, four male and
four female) 12–16 months old and weighing 20–32 kg,
were used. The animals were housed and fed twice daily
with an appropriate quantity of feed during the experi-
ment period. Water was supplied ad libitum. This study
was approved by the Animal Ethic Committee of Uni-
versity of Adnan Menderes. The animals were allocated
into three groups (Groups I, Group II and Group III) of
8 such that the mean weight and sex of animals in each
group was similar.
Drug administration and sampling
The study was designed according to two-phase cross-
over study protocol. A four-week washout period was30 40 50
e (h)




BZ-SO following subcutaneous administrations in sheep and goats at a
ats (n = 8)


























Fig. 6 Comparative mean (±SD) plasma concentration vs. time curves of ABZ-SO2 following subcutaneous administrations of ABZ-SO in sheep
and goats at a dose of 5 mg/kg and at increased dose rates (10 and 15 mg/kg) in goats (n = 8)
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8 sheep were assigned as Group I, and 16 goats were al-
located into two groups (Group II and III). For treat-
ment of the animals, ABZ-SO (ricobendazole; Rizal®
injectable, 100 mg/mL, Sanovel, Istanbul, Turkey) was
used.
In Phase 1, the treatments were as follows: Group I and
II (both subcutaneously: 5 mg/kg BW-recommended sheep
dose), and Group III (intravenously: 5 mg/kg BW). A four-
week washout period was allowed between the phases of
the study.Table 4 Comparative mean (±SD) kinetic parameters of ABZ-SO in g
dose rates (10 and 15 mg/kg) in goats following subcutaneous adm
Parameters Sheep G
5 mg/kg 5
T1/2λz (h) 4.99 ± 1.12* 2
Tmax (h) 8.50 ± 1.41 7
Cmax (μg/mL) 2.05 ± 0.37 1
Tlast (h) 38.00 ± 8.28* 2
AUClast (μg.h/mL) 38.35 ± 9.81* 2
MAT (h) 5.56 ± 2.07 4
MRTlast (h) 13.00 ± 1.54* 1
Cmax (μg/mL) (Normalized)a 2.05 ± 0.37 1
AUC (μg.h/mL) (Normalized)a 38.35 ± 9.81 2
F (%) 97.9*
T1/2λz terminal half-life; Tmax time to reach peak plasma concentration; Cmax peak pla
area under the (zero moment) curve from time 0 to the last detectable concentratio
*The parameters in sheep are significantly different from those in goats (*P < 0.05)
aAUC and Cmax values were dose-normalized dividing the observed value by 2 (10 m
bThe parameters in goats observed after a dose of 5 mg/kg are significantly differen
cThe parameters in goats observed after a dose of 10 mg/kg are significantly differeIn Phase 2, following treatments were performed:
Group I (intravenously: 5 mg/kg BW), Group II and III
(both subcutaneously; 10 and 15 mg/kg BW, respect-
ively). Because of the possible irritation at the injection
site, each of these doses (10 mg/kg and 15 mg/kg) were
divided into two injections and applied to left and right
side of the goats.
Heparinized blood samples (5 ml) were collected via
jugular venipuncture prior to drug administration (time 0)
and 1, 2, 4, 8, 12, 16, 24, 32, 48, 72, 96, 120 h after SC ad-
ministration. Additionally, 1, 5, 15, 30 and 90 min samplesoats and sheep at a dose rate of 5 mg/kg and at increased
inistrations (n = 8)
oats
mg/kg 10 mg/kg 15 mg/kg
.44 ± 0.37b 4.62 ± 1.51 5.79 ± 1.57
.43 ± 1.51 8.00 ± 2.31 7.50 ± 1.41
.98 ± 0.37b 3.40 ± 0.84c 6.30 ± 0.81
8.57 ± 4.28 36.57 ± 7.81 35.00 ± 8.49
9.76 ± 6.52b 62.19 ± 13.61c 112.66 ± 17.16
.53 ± 2.23b 7.07 ± 1.49 7.10 ± 1.30
0.34 ± 1.85 12.88 ± 1.19 12.50 ± 1.70
.98 ± 0.37 1.70 ± 0.42 2.10 ± 0.27
9.76 ± 6.52 31.09 ± 6.30 37.55 ± 5.72
82.0b 91.18c 110.01
sma concentration; Tlast time to last detectable plasma concentration; AUClast
n; MRTlast mean residence time; MAT mean absorption time; F bioavailability
g/kg) or 3 (15 mg/kg)
t from those in goats observed after doses of 10 and 15 mg/kg (&P < 0.05)
nt from those in goats observed after a dose of 15 mg/kg (&P < 0.05)
Table 5 Comparative mean (±SD) kinetic parameters of
ABZ-SO2 in goats and sheep following subcutaneous
administrations of ABZ-SO at a dose rate of 5 mg/kg and at
increased dose rates (10 and 15 mg/kg) in goats (n = 8)
Parameters Sheep Goats
5 mg/kg 5 mg/kg 10 mg/kg 15 mg/kg
T1/2λz (h) 4.57 ± 2.36* 1.92 ± 0.37 2.72 ± 0.88 2.43 ± 0.47
Tmax (h) 18.50 ± 4.75 17.14 ± 5.52
& 25.14 ± 3.02 26.00 ± 5.66
Cmax (μg/mL) 0.53 ± 0.10 0.68 ± 0.25& 1.41 ± 0.20 1.75 ± 0.26
Tlast (h) 42.00 ± 8.28* 30.86 ± 3.02 41.14 ± 8.55 46.00 ± 5.66
AUClast
(μg.h/mL)
12.34 ± 3.82 11.43 ± 3.20& 30.52 ± 6.84¥ 41.96 ± 6.55
MRTlast (h) 19.78 ± 3.42 16.16 ± 2.05 20.74 ± 3.02 20.79 ± 2.23
Cmax (μg/mL)
(Normalized)#
0.53 ± 0.10 0.68 ± 0.25 0.70 ± 0.10 0.58 ± 0.08
AUC (μg.h/mL)
(Normalized)#
12.34 ± 3.82 11.43 ± 3.20 15.26 ± 3.42 13.98 ± 2.18
T1/2λz terminal half-life; Tmax time to reach peak plasma concentration; Cmax
peak plasma concentration; Tlast time to last detectable plasma concentration;
AUClast area under the (zero moment) curve from time 0 to the last detectable
concentration; MRTlast mean residence time
*The parameters in sheep are significantly different from those in goats (*P < 0.05)
#AUC and Cmax values were dose-normalized dividing the observed value by 2
(10 mg/kg) or 3 (15 mg/kg)
&The parameters in goats observed after a dose of 5 mg/kg are significantly
different from those in goats observed after doses of 10 and 15 mg/kg (&P < 0.05)
¥The parameters in goats observed after a dose of 10 mg/kg are significantly
different from those in goats observed after a dose of 15 mg/kg (&P < 0.05)
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of intravenous groups. Blood samples were centrifuged at
2000 X g for 20 min, and plasma was harvested and trans-
ferred to plastic tubes. All plasma samples were stored
at−20 °C until the analyses.
Analytical procedures
Pure analytical standard compounds of ABZ, ABZ-
NH3, rac-ABZ-SO, ABZ-SO2 and internal standard of
oxibendazole (OBZ) were obtained from Dr. Ehrenstorfer
(Augsburg, Germany). A stock solution (100 μg/mL) of a
pure standard mixture was prepared with acetonitrile as
the solvent. This was diluted with acetonitrile-water
(25:75, v/v) to give 0.5, 1, 5, 10 and 20, 50 standard solu-
tions for calibration as standard curves and to add to the
drug-free plasma samples to determine the recovery.
Plasma concentrations of ABZ, ABZ-NH3, ABZ-SO
and ABZ-SO2 were estimated by high performance li-
quid chromatography (HPLC) with a liquid-liquid phase
extraction procedure adapted from that described by
Marriner and Bogan [3]. Briefly, drug-free plasma sam-
ples (1 ml) were spiked with standards of ABZ, ABZ-
NH3, rac-ABZ-SO and ABZ-SO2 to reach the following
final concentrations: 0.05, 0.1, 0.5, 1, 2, 5 and 10 μg/mL.
OBZ (0.5 μg/mL) was used as an internal standard. Am-
monium hydroxide (100 μl, 0.1 N, pH 10) was added
to 10 ml-ground glass tubes containing 1 mL spiked orexperimental plasma samples. After mixing for 15 s,
6 mL ethyl acetate was added. The sample tubes were
stoppered and shaken for 10 min on a slow rotary
mixer. After centrifugation at 3000 g for 10 min, the
upper organic phase (4 ml) was transferred to a thin-
walled 10 ml-conical glass tube and evaporated to dry-
ness at 40 °C in a rota vapour (Maxi-Dry plus, Heto,
Denmark).
The dry residue was reconstituted with 250 μl mobile
phase. Then the tubes were placed in an ultrasonic bath
and finally, 50 μl of this solution was injected into the
chromatographic system.
Chromatographic conditions
The mobile phase was a mixture of acetonitrile-water
to which glacial acetic acid was added (0.5 %, v/v). It
was pumped through the column (Luna nucleosil C18,
3 μm, 150 mm × 4.6 mm Phenomenex, Cheshire, UK)
with nucleosil C18 guard column (Phenomenex, Cheshire,
UK) in a linear gradient fashion changing from 10:90
(acetonitrile-water) to 85:15 for 11 min; 85:15 to 10:90 for
1 min and the last ratio was maintained for 5 min. The
flow rate was 1 ml/min. Samples were processed on a
computerized gradient HPLC system (1100 series, Agilent
Technologies, GmbH, Germany) comprising a degasser, a
quaternary pump (G1354A), an auto sampler (G1313), a
column oven (G1316A) and diode-array detector
(G1315B) set at 292 nm for all molecules.
The extracted samples were re-analysed by a chiral
stationary phase to determine the concentration of
ABZ-SO enantiomers. The enantiomers were estimated
by using chiral chromatography adapted from that pre-
viously described by Delatour et al. [11] with some
modifications. Briefly, a mobile phase of acetonitrile:-
water (7:93) was pumped at a flow rate of 1 ml/min
through a Chiral-AGP column (5 μm, 150 × 40 mm,
ChromTech, MN, USA) with ultraviolet detection at
292 nm for 6 min and then the mobile phase ratio was
changed to 100 % acetonitrile and maintained for 4 min
to wash column for less polar molecules and impurities
and finally the ratio changed to initial proportion and
(7:93) maintained for 3 min to prepare for the next
injection.
Method of calibration
The analytic methods used for ABZ, ABZ-NH3, rac-
ABZ-SO and ABZ-SO2 in plasma were validated prior
to the start of the study. The analyte was identified with
the retention times of the pure reference standards. Re-
coveries of the analytes were measured by comparison
of the peak areas from 7 spiked plasma samples with
the areas resulting from injection of external and in-
ternal standards. The inter-and inra-assay precisions of
the extraction and chromatography procedures was

























































































Fig. 7 Mean plasma concentrations of enantiomers [(+) ABZ-SO and (−) ABZ-SO)] vs. time curves of ABZ-SO in sheep (5 mg/kg-Fig. a) and goats
following subcutaneous administrations at doses of 5 (Fig. b), 10 (Fig. c) and 15 (Fig. d) mg/kg (n = 8)
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sheep and goat plasma samples containing known
amounts of the drugs on different days.
The limits of detection (LOD) and quantification
(LOQ) were determined based on signal to noise ratiosTable 6 Comparative mean (±SD) kinetic parameters of (−) ABZ-SO
administrations at dose rates of 5, 10 and 15 mg/kg (n = 8)
Parameters Sheep Goats
5 mg/kg 5 mg/kg
(−) ABZ-SO (+) ABZ-SO (−) ABZ-SO (+) A
T1/2λz (h) 6.23 ± 1.71 9.74 ± 6.40 4.56 ± 1.55 7.95
Tmax (h) 7.43 ± 1.51 9.14 ± 1.95 8.00 ± 0.00 8.80
Cmax (μg/mL) 0.95 ± 0.22 1.12 ± 0.21 0.92 ± 0.24 1.03
AUClast (μg.h/mL) 15.27 ± 2.67
* 28.22 ± 10.36 12.48 ± 4.14* 21.99
MRTlast (h) 12.20 ± 1.94
* 19.45 ± 7.91 10.20 ± 1.60 16.15
T1/2λz terminal half-life; Tmax time to reach peak plasma concentration; Cmax peak pla
the last detectable concentration; MRTlast mean residence time
*Differences between the enantiomers in the same animals and dose rates (P < 0.05of 3 and 10, respectively, taken by measuring the in-
stability of the baseline before and after each molecule
signal, using individual injections. Calibration curves
were fitted by use of 7 concentrations that ranged from
0.05 to 10 μg/mL for plasma samples.and (+) ABZ-SO in goats and sheep following subcutaneous
10 mg/kg 15 mg/kg
BZ-SO (−) ABZ-SO (+) ABZ-SO (−) ABZ-SO (+) ABZ-SO
± 4.59 4.79 ± 1.57 7.36 ± 3.51 4.85 ± 1.93* 7.57 ± 3.29
± 1.79 7.43 ± 1.51 10.29 ± 3.15 8.00 ± 0.00 8.00 ± 2.14
± 0.20 1.74 ± 0.45 1.75 ± 0.46 3.05 ± 0.33 3.38 ± 0.84
± 6.96 25.41 ± 4.93* 40.00 ± 9.03 44.12 ± 6.84* 74.73 ± 16.43
± 6.43 10.82 ± 1.26* 16.74 ± 3.27 10.34 ± 1.14* 16.49 ± 3.32
sma concentration; AUClast area under the (zero moment) curve from time 0 to
)
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The plasma concentration versus time curves obtained after
each treatment in individual animals were fitted with a soft-
ware program (WinNonlin, version 5.2, Pharsight Corp,
Mountain View, California) and reported as mean ± SD.
The pharmacokinetic parameters for each animal were
analysed via non-compartmental model analysis for both
administration routes. The Cmax and Tmax were obtained
from the plotted plasma concentration-time curve in each
animal. The trapezoidal rule was used to calculate the area
under the curve (AUC), and mean residence time (MRT)
from 0 to last time with a measurable concentration was
calculated by use of the following equation:
MRTlast ¼ AUMClast=AUClast
Where AUMClast is the area under the moment curve
from 0 to infinity and AUClast is the AUC from 0 to
infinity.
Terminal half-life (T1/2λz) was calculated as:
T1=2λz ¼ – ln 2ð Þ=λz
Where λz represent the first order rate constant asso-
ciated with the terminal (log linear) portion of the curve.
The mean absorption time (MAT) was calculated by the
following equations:
MAT ¼ MRTSC–MRTIV
The fraction of dose absorbed (ie, F) was calculated by
use of mean AUCs calculated for each route of adminis-
tration by use of the following equation:
F ¼ AUCSC  DIV= AUCIV  DSCð Þ  100
The pharmacokinetic parameters are reported as mean ±
SD. Pharmacokinetic parameters were statistically com-
pared with a one-way analysis of variance (ANOVA). All
statistical analyses were performed by using MINITAB for
Windows (release 12.1, Minitab Inc., State College, PA,
USA). Mean values were considered significantly different
at P < 0.05.
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